3Daughters, a Mansfield, MA-based clinical development company, raised over $2M in a first tranche of Seed funding.
The round was led by Thairm Bio, with a group of life science investors, and joined by the Argosy Foundation, Wexford Science and Technology, UMass Amherst, and other undisclosed investors.
The company intends to use the funds to advance its lead IUD asset, 3D-001, through an IND filing followed by a Phase 1 clinical trial this year.
Led by CEO Mary Beth Cicero, 3Daughters is a clinical development company focused on evolutionary healthcare for women. Its first product, (3D-001), is a frameless, magnetic, nonhormonal intrauterine device (IUD) for long-acting contraception that conforms to a woman’s body and is combined with its patented Slider™ system (insertion/ retrieval) designed for easy and less painful insertion and retrieval.
Commenting on the news, Mary Beth Cicero said: “We are thrilled to have garnered such strong support from our existing and new investors, all of whom share our vision of solving health issues for women. This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic. With this funding, we are getting closer to our promise to address significant and neglected issues, like IUD insertion pain, that women have been putting up with for over 50 years.”
FinSMEs
22/01/2024